| 1.23 0.03 (2.5%) | 11-07 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.75 | 1-year : | 1.97 |
| Resists | First : | 1.5 | Second : | 1.69 |
| Pivot price | 1.41 |
|||
| Supports | First : | 1.2 | Second : | 0.99 |
| MAs | MA(5) : | 1.3 |
MA(20) : | 1.43 |
| MA(100) : | 1.59 |
MA(250) : | 2.22 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 2.2 |
D(3) : | 6.9 |
| RSI | RSI(14): 33.9  |
|||
| 52-week | High : | 5 | Low : | 1.2 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ APRE ] has closed above bottom band by 9.6%. Bollinger Bands are 65.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.29 - 1.3 | 1.3 - 1.31 |
| Low: | 1.2 - 1.21 | 1.21 - 1.22 |
| Close: | 1.22 - 1.23 | 1.23 - 1.24 |
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
Mon, 03 Nov 2025
Aprea Therapeutics (Nasdaq: APRE) Transforms Cutting-Edge - openPR.com
Mon, 03 Nov 2025
Aprea Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview - TradingView
Mon, 27 Oct 2025
Aprea Therapeutics Advances ATRN-119 Study for Solid Tumors - TipRanks
Fri, 24 Oct 2025
Aprea Therapeutics (NASDAQ: APRE) advances APR-1051; three of four stable at 100 mg - Stock Titan
Wed, 15 Oct 2025
Aprea Therapeutics Shifts Focus to Combination Therapies - TipRanks
Wed, 15 Oct 2025
1,100 mg RP2D: Aprea Therapeutics shifts ATRN-119 to combination focus, pauses monotherapy enrollment - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 4.64e+006 (%) |
| Held by Institutions | 11.3 (%) |
| Shares Short | 85 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.477e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 868.2 % |
| Return on Equity (ttm) | -39.2 % |
| Qtrly Rev. Growth | 841010 % |
| Gross Profit (p.s.) | -50.65 |
| Sales Per Share | -43.3 |
| EBITDA (p.s.) | -5.61539e+006 |
| Qtrly Earnings Growth | -2.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -13 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.03 |
| Price to Cash Flow | 0.82 |
| Dividend | 0 |
| Forward Dividend | 49840 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|